Literature DB >> 7522742

Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.

Y Yang1, F A Nunes, K Berencsi, E Gönczöl, J F Engelhardt, J M Wilson.   

Abstract

Although first generation recombinant adenoviruses, deleted of sequences spanning E1a and E1b, have been useful for in vivo applications of gene therapy, expression of the recombinant gene has been transient and often associated with the development of inflammation. We show that with first generation adenovirus-mediated gene transfer to the mouse lung, viral proteins are expressed leading to destructive cellular immune responses and repopulation of the lung with nontransgene containing cells. Second generation E1 deleted viruses further crippled by a temperature sensitive mutation in the E2a gene were associated with substantially longer recombinant gene expression and less inflammation. Stable expression of human CF transmembrane conductance regulator has been achieved in lungs of CF mice instilled with a second generation virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522742     DOI: 10.1038/ng0794-362

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  98 in total

1.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 2.  Gene therapy of hepatic diseases: prospects for the new millennium.

Authors:  K Shetty; G Y Wu; C H Wu
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

3.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 4.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 5.  Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome.

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Hum Gene Ther       Date:  2012-06       Impact factor: 5.695

6.  Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.

Authors:  H Zhang; Y Yang; J L Horton; E B Samoilova; T A Judge; L A Turka; J M Wilson; Y Chen
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 7.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

8.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.

Authors:  A Lieber; C Y He; L Meuse; D Schowalter; I Kirillova; B Winther; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

9.  Efficient gene transfer into human hepatocytes by baculovirus vectors.

Authors:  C Hofmann; V Sandig; G Jennings; M Rudolph; P Schlag; M Strauss
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

10.  Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer.

Authors:  T Li; B L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.